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Background: The sequence effect (SE), defined as a reduction in amplitude of repetitive
movements, is a common clinical feature of Parkinson’s disease (PD) and is supposed
to be a major contributor to freezing of gait (FOG). During walking, SE manifests
as a step-by-step reduction in step length when approaching a turning point or gait
destination, resulting in the so-called destination sequence effect (dSE). Previous studies
explored the therapeutic effects of several strategies on SE, but none of them evaluated
the role of an intensive rehabilitative program.
Objectives: Here we aim to study the effects of a 4-week rehabilitative program on dSE
in patients with PD with and without FOG.
Methods: Forty-three patients (30 males, 70.6 ± 7.5 years old) with idiopathic PD were
enrolled. The subjects were divided into two groups: patients with (PD + FOG, n = 23)
and without FOG (PD – FOG, n = 20). All patients underwent a standardized 4-week
intensive rehabilitation in-hospital program. At hospital admission (T0) and discharge (T1),
all subjects were evaluated with an inertial gait analysis for dSE recording.
Results: At T0, the dSE was more negative in the PD+ FOG group (−0.80± 0.6) when
compared to the PD – FOG group (−0.39 ± 0.3) (p = 0.007), even when controlling for
several clinical and demographic features. At T1, the dSE was reduced in the overall
study population (p = 0.001), with a more pronounced improvement in the PD + FOG
group (T0: −0.80 ± 0.6; T1: −0.23 ± 0.4) when compared to the PD – FOG group
(T0: −0.39 ± 0.3; T1: −0.22 ± 0.5) (p = 0.012). At T1, we described in the overall
study population an improvement in speed, cadence, stride duration, and stride length
(p = 0.001 for all variables).
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Conclusions: dSE is a core feature of PD gait dysfunction, specifically in patients with
FOG. A 4-week intensive rehabilitative program improved dSE in PD patients, exerting a
more notable beneficial effect in the PD + FOG group.
Keywords: movement disorders, gait analysis, hypokinesia, basal ganglia, functional independence, movement
analysis, parkinsonism
INTRODUCTION
Gait impairment and freezing of gait (FOG) represent common
and disabling motor features of Parkinson’s disease (PD) (1). The
antiparkinsonian dopaminergic therapy positively modulates a
subset of gait parameters, such as speed of gait and stride length,
while its impact on FOG is limited (2, 3). Growing evidence
supports the efficacy of neurorehabilitation in the treatment of
PD across all phases of the disease (4). Rehabilitation becomes
crucial for the management of those symptoms that poorly
respond to the antiparkinsonian drugs. Several strategies, such
as action observation, cueing, and neuromodulation, have been
applied with positive results in the rehabilitation of gait and FOG
in PD, although the precise mechanisms underlying their effect
are largely elusive (5–7). A deep phenotyping of gait features
in individual patients as well as in different subtypes of PD will
improve our knowledge on gait pathophysiology, ideally leading
to tailored interventions (1). In the last years, the advent of
reliable wearable devices has prompted the widespread study of
several parameters of the parkinsonian gait in both clinical and
research settings (1, 8–11).
The sequence effect (SE), defined as a reduction in amplitude
of repetitive movements, is a common clinical feature of several
tasks of PD patients both in early and advanced stages of
the disease (12–14). During walking, SE manifests as a step-
by-step reduction in step length when approaching a turning
point or gait destination resulting in the so-called destination
sequence effect (dSE) (15, 16). Experimental and clinical evidence
supports the hypothesis that SE is a contributor to FOG (17, 18).
Indeed, the dual requirement hypothesis suggests that FOG may
be precipitated by the occurrence of SE over a constitutional
reduction of stride length (gait hypokinesia) (17, 19). SE is
specifically pronounced in PD patients affected by FOG, and it
arises immediately before a FOG episode induced by a turning
or a dual-task (16). SE may be triggered by several factors,
such as an obstacle, a cognitive task, or removal of visual or
integrative cues (20–22). The pathophysiology of SE is not
completely elucidated. The most accepted hypothesis ascribes SE
to a maladaptive basal ganglia process that fails to adjust gait
pattern to environmental changes (18, 23, 24). In this view, basal
ganglia are not able to provide appropriate information to the
supplementary motor area, leading to a failure of internal cues
and a reduction in the amplitude of automatic movement (17).
Apparently, such condition is unresponsive to dopaminergic
therapy supplementation, thereby representing an unmet clinical
need for PD patients.
SE may be acutely modulated by several rehabilitative
strategies such as split-belt treadmill (25) and reinforcement
of visual cues (16), while repetitive transcranial magnetic
stimulation (rTMS), antiparkinsonian dopaminergic
drug administration, and attention strategies were
found not to influence the SE (18, 26, 27). Kang et al.
demonstrated a positive effect of exercise training on SE
evaluated at upper limb in de novo PD patients (28),
while the evidence on the role of neurorehabilitation on
gait SE improvement and retention is extremely scarce
(16, 28).
Here we aim to study the effects of a 4-week intensive
rehabilitative gait program on the dSE in patients affected by PD
with and without FOG.
MATERIALS AND METHODS
Subjects
Forty-three patients (30 males, 70.6 ± 7.5 years old) with
idiopathic PD were consecutively enrolled among those
attending the Neurorehabilitation Department of the IRCCS
Mondino Foundation (Pavia, Italy) between August 2019 and
January 2021. Idiopathic PD was diagnosed according to the
Movement Disorders Society clinical diagnostic criteria for
PD (29). Inclusion criteria were as follows: age between 18
and 80 years; Hoehn and Yahr stage between I and IV; and
Mini-Mental State Examination score above 24. The exclusion
criteria were as follows: history of major psychiatric or other
neurological conditions; comorbid rheumatological, ophthalmic,
or orthopedic diseases; ongoing or previous treatment with
neuroleptic drugs; and any change in dose or regimen of the
antiparkinsonian therapy in the last month before enrolment.
The subjects were divided into two groups: (1) patients with
freezing of gait (PD + FOG) or (2) patients without freezing of
gait (PD – FOG). The presence of FOG was defined by a score
between 1 and 4 at either item “2.13 Freezing” or item “3.11
Freezing of gait” of the Unified Parkinson Disease Rating Scale
(UPDRS) (30). In the PD + FOG group, all patients enrolled
satisfied this criterion according to item “3.11 Freezing of gait”
of the UPDRS.
No modifications of the drug regimen were allowed during
the study.
The local ethics committee approved the study
(p-20190052441), and all participants signed a written
informed consent before enrollment. The trial was registered
at www.clinicaltrials.gov (NCT04921748). The authors agree
to share anonymized data from this analysis upon reasonable
request from qualified investigators. The study was completed in
February 2021.
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Study Procedures
At hospital admission (T0), the patients were evaluated by a
neurologist with expertise in neurorehabilitation and movement
disorders who collected a comprehensive anamnestic evaluation
and performed a complete neurological examination. If the
patient fulfilled inclusion/exclusion criteria and agreed to
participate in the study, the baseline procedures were completed
with an instrumental gait analysis and administration of a set of
clinical scales that included the following: a rating of PD-related
motor disability with the UPDRS part III (UPDRS-III) (30), with
score of item “3.11 Freezing of gait” of the UPDRS-III scale being
used as a measure of FOG; a rating of functional independence
through the Functional Independence Measure (FIM) (31); and
a rating of dependence in activity of daily living according to the
Barthel Index (32).
After that, patients underwent a 4-week intensive
rehabilitation program that consisted in individual training
sessions with a physiotherapist lasting at least 90min and
delivered daily for 6 days per week in an in-hospital setting (see
below for details about the strategies adopted). At the end of the
rehabilitation program (T1), the patients completed the study
procedure with the second instrumental gait analysis evaluation
and administration of the same set of clinical scales.
Gait Analysis and Sequence Effect
Computation
The gait analysis was performed with a wearable, wireless, inertial
system (BTS G-Walk, G Sensor—BTS Bioengineering S.p.A.,
Italy; weighs 37 g; dimensions 70× 40× 18mm). The device was
secured to the back of the patients between L5 and S1 vertebrae
with an ad hoc elastic belt around the waist. The G Sensor
recorded acceleration data through a triaxial accelerometer, a
triaxial gyroscope, and a triaxial magnetometer (sampling rate
100Hz). All data were transferred to a notebook and processed
with a dedicated software (BTS G-Studio, BTS Bioengineering
S.p.A., Italy). Gait evaluation validity and reproducibility with the
G-Walk system, and inertial sensors in general, were previously
demonstrated in healthy subjects as well as in PD (1, 8–11).
Gait assessment was performed by an expert technician (V.G.)
in a straight hallway (35 × 2.5m wide) without obstacles or
factors that might contribute to FOG.
All subjects were recorded in the morning (between 9:00 and
11:00 a.m.) and inON condition. After themontage of the inertial
system, the subjects stood in a comfortable upright standing
position, waiting to start walking. When the technician gave
the order, the subjects started to walk at a comfortable pace for
20m. The subjects independently stopped at the end of the 20-
m pathway, which was clearly marked by a straight line on the
ground. Gait assessments were discarded if episodes of FOG or
pauses occurred during the walk. The subjects were allowed to
rest according to their needs and preferences. For each subject,
three optimally performed gait assessments were recorded. In
the off-line analysis, the first and last strides of each walk were
excluded (to avoid interference of fast acceleration/deceleration
at gait starting/ending), and the remaining strides were used
for the evaluation of gait parameters. For gait parameters,
the average value of the three gait assessments was used.
The following parameters were recorded and analyzed: speed
(meters/second), cadence (steps/minute), stride length (meters),
step length (meters), stride duration (seconds), single support,
double support, swing duration, and stance duration (percentage
stride distribution) (33).
The dSE was computed as a regression slope (β) of step length
according to a previously described and validated methodology
where step length is plotted against step number (16–18). The
regression slope represents the decrease (negative values) or
increase (positive values) in step length. In an off-line analysis,
a step-by-step raw data of each gait assessment was extracted.
As previously described, the last stride was excluded to avoid
interference of sharp deceleration before gait ending. The length
of the last six steps (y) ahead of the final stride was then plotted
against step number (x), and the linear regression slope (β) was
calculated as a measure of dSE (16–18, 26). In addition, the
intercept (I) of the regression curve was used as an indirect
measure of gait hypokinesia (17, 18). For each group, the
relationship between gait hypokinesia and sequence effect is
expressed by the function of the linear regression as follows: y
= β (x)+ I.
Rehabilitation Treatment
All patients enrolled were treated with an in-hospital
rehabilitation program focused on the rehabilitation of
gait disorder in PD (7, 34). The rehabilitation program
was delivered according to local regional regulation
(https://www.sitilombardia.it/wp-content/uploads/2015/
04/Requisiti-accreditamento-Riabilitazione_dgr_1980_
14.pdf), validated rehabilitation protocols in use at
our center (7, 35, 36) and in agreement with the
European Physiotherapy Guideline for Parkinson Disease
(file:///E:/2021/NRB%202021/eu_guideline_parkinson_guideline_
for_pt_s1.pdf). The rehabilitation program was delivered
by a team of physiotherapists with high expertise in
neurorehabilitation and, specifically, in the rehabilitation of
movement disorders. The rehabilitation treatment included
passive, active-assisted, and active exercises according to
evidence-based methods (37, 38). Each session consisted of
isotonic and isometric exercises for the major muscles of the
limbs and trunk, cardiovascular warm-up exercises, muscle
stretching exercises for functional purposes, balance training
exercises, specific motor exercise for hypokinesia, and 45
minutes of overground gait training. This latter was delivered
without the use of devices or cueing strategies and was based
on a conventional approach, which was individualized for
each patient in the frame of the strategies proposed by the
European Physiotherapy Guidelines for Parkinson’s Disease.
More specifically, we used a combination of:
- Walking taking large steps, with large amplitude arm swing;
- Walking around and over obstacles;
- Walking with sudden stops and change in direction, including
backward walking;
- Walking while dual tasking;
- Walking and turning around in open or narrow spaces;
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TABLE 1 | Baseline clinical and demographic features of the study population.
All patients PD + FOG PD – FOG p-value
N 43 23 20 –
Age (years) 70.5 ± 7.5 72.4 ± 5.6 68.4 ± 8.9 0.080
Sex (male) 82.6% (19) 55.0% (11) 0.094
PD duration (years) 9.6 ± 6.2 11.5 ± 6.1 7.3 ± 5.6 0.025
Most affected side at PD onset Left 62.8% (27) 52.2% (12) 75.0% (15) 0.206
Right 37.2% (16) 47.8% (11) 25.0% (5)
Type of PD at onset Akinetic-rigid 48.8% (21) 39.1% (9) 60.0% (12) 0.227
Tremor-dominant 51.2% (22) 60.9% (14) 40.0% (8)
Patients with festination 23.3% (10) 30.4% (7) 15.0% (3) 0.294
Patients with frequent falls 34.9% (15) 39.1% (9) 30.0% (6) 0.749
Ongoing antiparkinsonian therapy Levodopa 95.3% (41) 95.7% (22) 95.0% (19) 0.428
Dopamine agonist 69.8% (30) 78.3% (18) 60.0% (12)
COMT inhibitor 2.3% (1) 4.3% (1) 0.0% (0)
MAO-B inhibitor 23.2% (10) 30.4% (7) 15% (3)
Hoehn & Yahr stage Stage I 25.6% (11) 17.4% (4) 35.0% (7) 0.141
Stage II 37.2% (16) 30.4% (7) 45.0% (9)
Stage III 32.6% (14) 43.5% (10) 20.0% (4)
Stage IV 4.7% (2) 8.7% (2) 0.0% (0)
Levodopa equivalent daily dose (mg) 859.4 ± 306.6 959.1 ± 301.2 744.8 ± 277.3 0.020
UPDRS-III total score 31.1 ± 9.9 34.1 ± 10.3 27.7 ± 8.5 0.035
FIM score 91.7 ± 12.1 87.8 ± 13.1 96.1 ± 9.4 0.024
Barthel Index 68.7 ± 14.4 65.0 ± 15.5 73.0 ± 11.9 0.069
COMT, catechol-O-methyltransferase; MAO-B, monoamine oxidase B; PD + FOG, patients affected by freezing of gait; PD – FOG, patients not affected by freezing of gait; PD,
Parkinson’s disease; FOG, freezing of gait; UPDRS-III, Unified Parkinson’s Disease Rating Scale part III (motor examination); FIM, Functional Independence Measure. Table entries in
bold indicate significant comparisons. Patients with frequent falls were defined as those who experienced at least five falls in the past 6 months (39).
- Climbing steps or stairs.
- The rehabilitation program was similar for the PD+ FOG and
PD – FOG groups.
Statistical Analysis
The sample size was calculated with freeware software
G∗Power (Version 3.1.9.6—University of Kiel, Germany)
for a two-factor repeated measures ANOVA, considering
as significant an effect size f of at least 0.30. The
computation was made with the following parameters: α
= 0.05; power = 95%; number of groups = 2; number
of measurements = 2; correlation among repeated
measures = 0.5; and non-sphericity correction = 1.
The minimum sample size suggested was 40 patients,
drop-outs excluded.
The Statistical Package for the Social Sciences
(SPSS), version 21.0 (Windows), was used for all
the computations. The Kolmogorov–Smirnov test
confirmed a normal distribution of our data. Continuous
variables are presented as mean ± standard deviation,
while categorical data are presented as percentage
(absolute number).
A univariate group comparison was performed with
a Student’s t-test for continuous variables, and statistical
association among categorical variables was tested with
Pearson χ2 test or Fisher’s exact test, if appropriate.
According to the results of the univariate analysis, a
multivariate binary logistic regression analysis (dependent
variable: PD + FOG vs. PD – FOG; covariates: clinical
variables found to be significantly associated to FOG at
univariate analysis) was performed according to a forward
stepwise method.
A correlation analysis was performed with Pearson’s test to
evaluate the role of speed of gait on dSE and I.
Outcome measures were analyzed with a two-way repeated
measures ANOVA with within-group TIME (2 levels: T0 vs. T1)
and between-groups GROUP (2 levels: PD + FOG vs. PD –
FOG) factors, followed by a post-hoc analysis with Bonferroni’s
correction. Gait parameters with left/right evaluations were
analyzed by adding a within-group factor SIDE (left and right)
to the ANOVA.
The level of significance was set at α = 0.05, always corrected
for multiple comparisons where appropriate.
RESULTS
Clinical and Demographic Features of
Study Population
Among the 43 PD patients enrolled, 23 had freezing of gait
(PD + FOG group: 19 males, 72.4 ± 5.6 years old) while the
remaining 20 did not (PD – FOG group: 11 males, 68.4 ±
8.9 years old). Clinical and demographic features are presented
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TABLE 2 | Baseline gait features of the study population.
All patients PD + FOG PD – FOG p-value
Sequence effect (dSE) −0.61 ± 0.5 −0.80 ± 0.6 −0.39 ± 0.3 0.007
Intercept (I) 47.4 ± 13.0 44.7 ± 11.3 50.5 ± 14.4 0.146
Speed (m/s) 0.73 ± 0.28 0.66 ± 0.25 0.81 ± 0.32 0.107
Cadence (steps/min) 101.59 ± 16.71 102.63 ± 19.24 100.56 ± 14.19 0.694
Left side
Stride duration (s) 1.23 ± 0.21 1.23 ± 0.24 1.23 ± 0.18 0.981
Stride length (m) 0.87 ± 0.29 0.79 ± 0.22 0.97 ± 0.34 0.046
Stance (%) 60.46 ± 3.85 61.26 ± 3.66 59.54 ± 3.94 0.146
Swing (%) 39.53 ± 3.85 38.73 ± 3.66 40.45 ± 3.94 0.146
Double support (%) 10.26 ± 2.52 10.41 ± 2.65 10.08 ± 2.43 0.676
Single support (%) 39.21 ± 3.67 39.38 ± 3.54 39.01 ± 3.90 0.746
Right side
Stride duration (s) 1.24 ± 0.21 1.23 ± 0.24 1.24 ± 0.18 0.966
Stride length (m) 0.87 ± 0.29 0.79 ± 0.22 0.97 ± 0.34 0.046
Stance (%) 61.78 ± 6.65 60.66 ± 3.61 63.07 ± 8.91 0.241
Swing (%) 39.02 ± 3.88 39.17 ± 3.79 38.85 ± 4.07 0.789
Double support (%) 10.96 ± 2.81 11.48 ± 2.88 10.36 ± 2.68 0.199
Single support (%) 39.61 ± 3.94 38.75 ± 3.67 40.61 ± 4.09 0.123
PD + FOG, patients affected by freezing of gait; PD – FOG, patients not affected by freezing of gait; PD, Parkinson’s disease. Intercept (I) is the measure of gait hypokinesia. Table
entries in bold indicate significant comparisons.
in Table 1. When compared to PD – FOG patients, the PD
+ FOG group showed higher doses of levodopa equivalent
daily dose (p= 0.020) and higher UPDRS-III score (p = 0.035)
with lower FIM score (p = 0.024). These differences indicate a
more advanced PD stage and higher level of disability in PD +
FOG, which may be related to the longer duration of disease
(p= 0.025).
Sequence Effect and Gait Analysis
Parameters at Baseline
The dSE was more negative (namely, the progressive step length
reduction was markedly reduced when approaching destination)
in the PD+ FOG group (−0.80± 0.6) when compared to the PD
– FOG group (−0.39± 0.3) (p= 0.007). By contrast, the intercept
I was comparable between study groups (PD+ FOG: 44.7± 11.3;
PD – FOG: 50.5± 14.4; p= 0.146).
At baseline, the PD + FOG and PD – FOG groups were
comparable in speed, cadence, stride duration, and percentage
distribution of stance, swing, double support, and single support.
By contrast, left and right stride lengths were shorter in the PD+
FOG group when compared to patients without FOG (p = 0.046
for both left and right strides) (Table 2).
A multivariate binary logistic regression analysis was
performed to evaluate the role of clinical and gait features
(covariates: PD duration, UPDRS-III score, FIM score, levodopa
equivalent dose, dSE, and left and right stride length) that were
found to be significantly associated to FOG (dependent variable:
PD + FOG group vs. PD – FOG group) in univariate analysis.
The only variables that survived the multivariate regression (R2:
0.483) were dSE (p = 0.007; B = 3.795) and levodopa equivalent
daily dose (p= 0.006; B=−0.005).
Effect of the Rehabilitation Program on
Sequence Effect and Gait Hypokinesia
The dSE improved at the end of the rehabilitation period in
the overall study population (T0: −0.63 ± 0.5; T1: −0.23 ±
0.4; factor TIME: p = 0.001). A significant TIME × GROUP
interaction (p= 0.012) was consistent with a more pronounced
improvement of dSE in the PD + FOG group (T0: −0.80 ± 0.6;
T1: −0.23 ± 0.4; post-hoc T0 vs. T1: p = 0.001) when compared
to the PD – FOG group (T0: −0.39 ± 0.3; T1: −0.22 ± 0.5; post-
hoc T0 vs. T1: p= 0.173). At T1, the dSE was comparable between
the PD+ FOG and PD – FOG groups (factor GROUP: p= 0.087;
post-hoc PD + FOG vs. PD – FOG at T1: p = 0.789) (Table 3;
Figure 1).
By contrast, intercept I, a measure of gait hypokinesia, was not
significantly modified by the rehabilitative intervention (factor
TIME: p = 0.741), regardless of the presence of FOG (factor
GROUP: p = 0.096; TIME × GROUP interaction: p = 0.739)
(Table 3; Figure 1). Speed of gait did not correlate with dSE at
T0 (p = 0.268) as well as at T1 (p = 0.663). By contrast, speed of
gait was significantly associated with intercept I at T0 (Pearson:
0.831, p= 0.001) and at T1 (Pearson: 0.834, p= 0.001).
The average regression curves of the two study groups are
presented in Figure 2.
Effect of Rehabilitation Program on Other
Gait Analysis Parameters
When the overall study population was considered, at the end
of the rehabilitation program (T1), we described a significant
improvement in speed (factor TIME: p = 0.001), cadence (factor
TIME: p = 0.001), stride duration (factor TIME: p = 0.001), and
stride length (factor TIME: p= 0.004). The modification of these
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TABLE 3 | Effect of the rehabilitation program on gait parameters and clinical scale scores.
T0 T1 ANOVA for repeated measures
PD + FOG PD – FOG PD + FOG PD – FOG TIME GROUP TIME × GROUP
Gait analysis parameters
Sequence effect (dSE) −0.80 ± 0.6 −0.39 ± 0.3 −0.23 ± 0.4 −0.22 ± 0.4 0.001 0.087 0.012
Intercept (I) 44.7 ± 11.3 50.5 ± 14.4 44.7 ± 12.9 51.7 ± 16.2 0.741 0.096 0.739
Speed (m/s) 0.66 ± 0.25 0.81 ± 0.32 0.87 ± 0.29 0.95 ± 0.30 0.001 0.170 0.412
Cadence (steps/min) 102.63 ± 19.24 100.56 ± 14.19 107.38 ± 18.86 106.29 ± 14.85 0.001 0.757 0.714
Stride duration (s) 1.23 ± 0.24 1.23 ± 0.18 1.16 ± 0.22 1.16 ± 0.17 0.001 0.977 0.885
Stride length (m) 0.79 ± 0.22 0.97 ± 0.34 0.97 ± 0.31 1.06 ± 0.29 0.004 0.089 0.333
Stance (%) 60.96 ± 3.63 61.30 ± 6.42 61.31 ± 3.85 61.34 ± 5.75 0.797 0.803 0.841
Swing (%) 38.95 ± 3.72 39.65 ± 4.00 38.82 ± 3.39 39.56 ± 3.50 0.744 0.224 0.943
Double support (%) 10.94 ± 2.76 10.22 ± 2.55 11.09 ± 2.60 10.59 ± 2.49 0.406 0.278 0.721
Single support (%) 39.06 ± 3.60 39.81 ± 4.49 36.56 ± 4.67 39.46 ± 3.16 0.850 0.620 0.278
Clinical scale scores
UPDRS-III total score 34.1 ± 10.3 27.7 ± 8.5 26.0 ± 9.0 22.4 ± 6.5 0.001 0.058 0.130
FIM score 87.8 ± 13.1 96.1 ± 9.4 101.8 ± 12.8 108.3 ± 9.0 0.001 0.031 0.436
Barthel Index 65.0 ± 15.5 73.0 ± 11.9 83.0 ± 14.3 89.7 ± 10.1 0.001 0.044 0.747
PD+ FOG, patients affected by freezing of gait; PD – FOG, patients not affected by freezing of gait; PD, Parkinson’s disease; FOG, freezing of gait. UPDRS-III, Unified Parkinson’s Disease
Rating Scale part III (motor examination); FIM, Functional Independence Measure. Intercept (I) is the measure of gait hypokinesia. Table entries in bold indicate significant comparisons.
FIGURE 1 | Effect of the rehabilitation program on destination sequence effect (dSE) and hypokinesia (measured by intercept “I”). dSE, destination sequence effect; I,
intercept of regression curve (measure of gait hypokinesia); T0, hospital admission; T1, end of the 4-week rehabilitation program—hospital discharge; PD + FOG,
patients with Parkinson’s disease with freezing of gait (black lines—n = 23); PD – FOG, patients with Parkinson’s disease without freezing of gait (red lines—n = 20).
Two-way repeated measures ANOVA with within-group TIME (T0 vs. T1) and between-groups GROUP (PD + FOG vs. PD – FOG) factors. (A) dSE: TIME: p = 0.001;
GROUP: p = 0.087; TIME × GROUP: p = 0.012. The dSE improved at the end of the rehabilitation period in the overall study population, with a more pronounced
improvement in the PD + FOG group when compared to the PD–FOG group. At T1, the dSE was comparable between the PD + FOG and PD – FOG groups (p =
0.789). (B) I: TIME: p = 0.741; GROUP: p = 0.096; TIME × GROUP: p = 0.739. Gait hypokinesia measured by I was not significantly modified by the rehabilitative
intervention, regardless of the presence of FOG.
parameters was not associated to the presence/absence of FOG
(factor GROUP and interaction TIME × GROUP: p > 0.050 for
all comparisons).
Stance, swing, double support, and single support of gait were
not modified by the rehabilitative intervention (factor TIME:
p > 0.050 for all comparisons) (Table 3). For all gait parameters
with left/right evaluations, factor SIDE was not significant, and it
was not considered for results interpretation.
Effect of Rehabilitation Program on Clinical
Scale Scores
When the overall study population was considered,
at the end of the rehabilitation program (T1), we
documented a significant improvement in UPDRS-
III (factor TIME: p = 0.001), FIM (factor TIME: p =
0.001), and Barthel Index scores (factor TIME: p = 0.001)
(Table 3).
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FIGURE 2 | Regression curves of study groups before (T0) and after (T1) the 4-week rehabilitation program. PD + FOG: patients with Parkinson’s disease with
freezing of gait (black lines—n = 23). PD – FOG: patients with Parkinson’s disease without freezing of gait (red lines—n = 20). The length of the last six steps (y-axis)
ahead of the final stride of gait was plotted against step number (x-axis). The linear regression slope (β) was calculated as a measure of the destination sequence
effect (dSE). The intercept (I) of the regression curve represented an indirect measure of gait hypokinesia. For each group, the relationship between gait hypokinesia
and sequence effect is expressed by the function of the linear regression as follows: y = β (x) + I. Dashed lines: regression curves of study groups at T0 (hospital
admission). Continuous lines: regression curves of study groups at T1 (end of the 4-week rehabilitation program—hospital discharge). Descriptively, at T0 (hospital
admission) the PD + FOG group (black dashed line) was characterized by a greater negative slope (more pronounced dSE) and a lower position (reduced step length
and pronounced gait hypokinesia) when compared to the PD – FOG group (red dashed line). At the end of the 4-week rehabilitation program (T1), we found a
reduction of the linear regression slope (β), which is consistent with a dSE improvement in the overall study population. This improvement was more pronounced in
the PD + FOG group (black continuous line), leading to a slope of the regression curve almost parallel to the PD – FOG group (red continuous line).
The modification of FIM, UPDRS-III, and Barthel Index
scores were not associated to the presence/absence of FOG
(interaction TIME × GROUP: p > 0.050 for all comparisons)
(Table 3).
In the PD + FOG group, the score of item “3.11 Freezing of
gait” of the UPDRS-III scale improved at T1 (T0: 1.4 ± 1.1; T1:
0.6± 0.7; p= 0.001).
DISCUSSION
In the present study, we evaluated the role of a 4-week intensive
rehabilitative program with overground gait training on the
dSE in PD patients with and without FOG. The dSE is a
physiological step-by-step reduction in step length that occurs
when a subject approaches the end of gait, probably representing
a safety strategy toward a planned gait termination (15). dSE may
become pathological when particularly pronounced as in PD and
specifically in patients with FOG (16–18).
The main results of our study may be summarized as follows:
(i) dSE is more pronounced in PD patients with FOG (PD
+ FOG group), being the association with FOG confirmed by
a multivariate analysis controlled for several variables; (ii) the
rehabilitative program positively modulated dSE in PD patients,
with a beneficial effect more pronounced in the PD+ FOG group
that achieved dSE values comparable to the PD – FOG group
at the end of rehabilitation; and (iii) neurorehabilitation plays
a pivotal role in the management of some gait disorders in PD,
as demonstrated by the improvement in speed, cadence, stride
duration, and stride length at T1 in the overall PD cohort.
The baseline clinical and demographic parameters of our
study population are in line with available literature (16, 17,
21). Indeed, PD + FOG patients had longer disease duration,
more severemotor disability (UPDRS-III score), lower functional
independence (FIM score), higher levodopa equivalent daily
dose, and shorter stride length. The percentage of patients
with frequent falls or festination was similar between groups,
although these associated clinical features were numerically more
prevalent in the PD+ FOG group, as expected (18, 39, 40).
The association between SE and a FOG phenotype is not a
novel finding. Chee et al. demonstrated greater SE in PD + FOG
patients when compared to the PD – FOG group and healthy
controls (17). In line with our results, Cao et al. reported greater
SE in PD+ FOG patients when compared to PD – FOG patients,
even when the analysis was controlled for clinical features (e.g.,
disease duration, UPDRS-III, andHoehn and Yahr stage) and gait
(step length and step length variability) (16).
Previous studies explored the therapeutic effects of several
strategies on SE, but none of them evaluated the role of an
intensive rehabilitative program (16, 25, 28). Cao et al. confirmed
that visual cueing delivered through floor transverse strips could
effectively reduce FOG episodes by improving step length and
dSE, leading to comparable dSE values between PD + FOG
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and PD – FOG patients under acute cueing conditioning (16).
According to their hypothesis, only strategies that eliminate SE
may treat FOG successfully. This idea was supported by the fact
that wearable laser lights, although improving step length, did not
improve dSE and failed to reduce FOG episodes. This hypothesis
fits well with the dual requirement theory that suggests that FOG
may be precipitated by the occurrence of SE over a constitutional
reduction of stride length (gait hypokinesia) (17, 19).
Fasano et al. studied a cohort of PD patients during split-
belt walking training in three conditions: (i) with the two belts
moving at the same speed (tied configuration); (ii) with reduced
speed of the belt on the side of the lower limb with shorter step
length; and (iii) with reduced speed of the belt on the side of
the lower limb with longer step length (25). They demonstrated
a worsening in SE in the late phase of the condition where the
belt speed of the best side (longer step length) was slowed (25).
This observation supports the idea that gait asymmetry may be
a precipitating factor for SE and FOG, probably as a result of
a shared maladaptive motor behavior that results in a defective
scaling of movement amplitude (25, 41).
Another interesting observation was provided by Chee et al.
(17). Experimentally reducing the step length of PD patients up to
75% of the normalized baseline step length led to a worsening of
SE only in PD+ FOG patients, but not in PD – FOG and healthy
controls groups (17). This is in line with the more pronounced
improvement of dSE we observed in PD + FOG patients at the
end of the neurorehabilitation program. These findings suggest
that SE not only appears to be a salient feature of PD +
FOG patients but also seems more amenable to modulation by
environmental interventions in this phenotype when compared
to PD – FOG patients and healthy controls. The added value
of our study is the demonstration of gait improvement to a
rehabilitation protocol that can be applied in the clinical setting,
instead of an experimental condition.
SE is poorly affected by levodopa administration (27, 42).
Indeed, PD patients in ON medication state showed higher SE
than healthy controls, with this impairment being reversed by
visual feedback administration (27). This observation was in line
with the results by Iansek et al. (18). In PD patients with FOG and
festination, SE was alleviated by visual cues administration, but
not by dopaminergic medication or pure attentional strategies
(18). Kang et al. demonstrated that motor training improved
bradykinesia and the SE at the upper limb in patients with de
novo PD in OFF state. Conversely, the SE did not improve with
exercise when tested under dopaminergic medication (28). rTMS
delivered over the supplementary motor area (SMA) improved
several gait parameters in PD (namely, speed, cadence, and
step count) and exerted a long-lasting beneficial effect on FOG
without directly influencing the SE (26).
The pathophysiology underlying the SE is yet to be completely
elucidated. A major role seems to be played by the inability
of the basal ganglia/SMA circuitry to provide a proper internal
timing and cue production as well as an adequate movement
scaling (12, 16, 27, 43, 44). Although isolated motor tasks may
be preserved in PD, the typical internal cueing deficit may impact
the automatic execution of a repetitive motor plan, leading to a
gradual amplitude reduction and SE (12, 45).
If the basal ganglia/SMA system appears to be crucial in the
SE generation, it is difficult to hypothesize that our rehabilitative
interventions might exert a positive modulation of SE trough this
pathway. This idea is corroborated by the lack of efficacy on SE
of either L-dopa administration, which mainly acts at the basal
ganglia level, or rTMS direct modulation of SMA (18, 26–28, 42).
By contrast, the consistent effects of the cueing and
rehabilitative strategies suggest the SE may be modulated trough
activation of the so-called lateral system, which includes the
parietal and premotor cortices, and the cerebellum (2, 46, 47).
Indeed, activation of the lateral system, and specifically of the
cerebellum, by means of exercise or external environmental
pacing may induce motor improvement by compensating the
hypoactive internal rhythmic signal generator in PD (43, 44, 48).
Technical and methodological issues (namely, a different gait
analysis tool and the evaluation of SE in different gait phases)may
explain the observed discrepancies. Another concern may exist
on the possible association between the modifications of dSE and
speed of gait improvement at the end of rehabilitation; indeed,
several gait parameters appear to be speed dependent (49). In
our study, the following observations contradict this hypothesis:
(i) a correlation analysis excluded a direct association between
dSE and speed of gait at T0 as well as T1; (ii) speed of gait was
not significantly different between the PD + FOG and PD –
FOG groups; and (iii) speed of gait improvement was comparable
between PD + FOG and PD – FOG patients, while dSE was
specifically modified in the PD+ FOG group.
The main strength of this study is that it documents dSE
improvement with rehabilitation and opens some new avenues
for rehabilitation applications to patients with FOG and SE.
Our report has several limitations that must be acknowledged.
While we extensively recorded anamnestic and clinical data
of our PD patients, we did not rate the severity of FOG
with a dedicated clinical scale such as the freezing of gait
questionnaire. Our primary aim was to evaluate the role of a
rehabilitation program on the dSE and not on FOG, but, based
on present results, we believe that a more precise phenotyping
of FOG may be relevant in future studies. Indeed, with this
limitation, it is difficult to clearly state the real relationship
between dSE improvement and FOG. In the present study, we
enrolled a population without cognitive impairment (MMSE
>24), which of course limits generalization to a PD population
with different clinical features. In addition, the absence of
a control group and a comprehensive rehabilitation program
does not allow to explore whether dSE improvement can be
ascribed to intensity of rehabilitation. Finally, we demonstrated
a role of neurorehabilitation on gait dSE at the end of a
4-week rehabilitation program, but we did not assess the
long-term effects, the duration of dSE improvement after
neurorehabilitation, and whether our findings result in reduced
risk of falls, which are frequent complications of FOG.
CONCLUSIONS
Gait dSE represents a pathogenetic feature of PD, being more
pronounced in patients with FOG. Our results demonstrate
that a 4-week intensive, in-hospital, rehabilitation program
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significantly reduces dSE in PD patients with FOG. dSE
improvement may reduce FOG episodes by targeting one of
the underlying pathophysiological mechanisms discussed above.
Further research is needed to better address the relationship
between SE and FOG as well as the long-term effects of
neurorehabilitation on these parameters.
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